Brief: FDA Approves Genio 2.1 For Use In Dream U.S. Ide Pivotal Study
June 1 (Reuters) -
* FDA APPROVES GENIO® 2.1 FOR USE IN DREAM U.S. IDE PIVOTAL
STUDY
Source text for Eikon: ID:nGNXz16C8
Further company coverage: NYXH.BR
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer